Wählen Sie die Sprache / Choose your language:
Current Events

Gastvortrag Joke MM den Haan

Date: 29 November 2019
Summary: CD169+ macrophages in lymphoid organs: Border patrol against infections and opportunity for vaccination strategies
more >>

Division of Virology
Department of Hygiene,
Microbiology, Social Medicine
Medical University IBK

Peter-Mayr-Straße 4b
A-6020 Innsbruck

Tel.: 0512/9003-71701
Fax: 0512/9003-73701
E-Mail: virologie@i-med.ac.at
Project Group Dr. Dorothee von Laer
Research Focus

Oncolytic viruses: The vesicular stomatitis virus (VSV) is a highly potent cancer destroying (oncolytic) virus, but neurotoxicity has limited its clinical application in the past. We are currently developing highly potent but less neurotoxic oncoloytic VSV variants by exchanging the envelope glycoprotein (VSV-GP) and/or distributing the viral genes onto two viral genomes (complementary replicating VSV). A spin-off of Innsbruck Medical University - ViraTherapeutics GmbH - will take the lead in the further development of VSV-GP. First-in-man clinical trials are exptected in three years. (Houskapreis 2013).

Gene therapy of HIV infection: In the past years we developed a novel antiviral gene that efficiently inhibits HIV infection at the level of cell entry. This serves as the basis of a novel gene therapy strategy for HIV infection, which is currently tested in a clinical trial. (Calimmune).


  • Dorothee von Laer, group leader, (Curriculum Vitae)
  • Monika Petersson, Postdoc
  • Tobias Nolden, Postdoc
  • Lisa Pipperger, M.Sc., PhD student
  • Anika Bresk, M.Sc., PhD
  • Bettina Großlercher, technician
  • Jasmine Rinnofner, MTA


Click this link to open publications of this project group (Link pupmed)

Weitere Links